Health Care & Life Sciences » Biotechnology | Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,212
580
1,032
1,702
2,489
3,049
Cost of Goods Sold (COGS) incl. D&A
130
93
125
210
275
410
Gross Income
1,082
488
908
1,492
2,214
2,639
SG&A Expense
1,281
1,129
1,372
1,481
1,816
1,974
EBIT
199
641
-
11
398
665
Unusual Expense
704
80
2
1
289
28
Non Operating Income/Expense
50
59
7
4
67
3
Interest Expense
23
73
84
81
58
34
Pretax Income
976
735
558
67
16
600
Income Tax
289
7
30
17
107
1,487
Consolidated Net Income
688
742
588
84
91
2,087
Net Income
445
738
556
112
263
2,096
Net Income After Extraordinaries
445
737
556
112
263
2,096
Net Income Available to Common
445
739
556
112
263
2,096
EPS (Basic)
1.98
3.14
2.31
0.46
1.04
8.09
Basic Shares Outstanding
225
235
241
245
249
254
EPS (Diluted)
1.98
3.14
2.31
0.46
1.04
8.09
Diluted Shares Outstanding
225
235
241
245
253
259
EBITDA
151
578
402
73
459
738
Minority Interest Expense
243
4
32
28
172
10
Other After Tax Income (Expense)
-
-
-
-
-
1

About Vertex Pharmaceuticals

View Profile
Address
50 Northern Avenue
Boston Massachusetts 02210
United States
Employees -
Website http://www.vrtx.com
Updated 07/08/2019
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. The company was founded by Joshua S.